ITCI Stock Overview
A biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 6/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Intra-Cellular Therapies, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$66.84 |
| 52 Week High | US$84.89 |
| 52 Week Low | US$45.50 |
| Beta | 1.01 |
| 1 Month Change | 3.21% |
| 3 Month Change | -10.75% |
| 1 Year Change | 5.41% |
| 3 Year Change | 75.53% |
| 5 Year Change | 411.01% |
| Change since IPO | 568.40% |
Recent News & Updates
Recent updates
Intra-Cellular: More Upside Possible Even After Positive MDD Treatment Data
Apr 16Intra-Cellular Therapies, Inc.'s (NASDAQ:ITCI) P/S Is On The Mark
Apr 09
We're Interested To See How Intra-Cellular Therapies (NASDAQ:ITCI) Uses Its Cash Hoard To Grow
Mar 17Intra-Cellular Therapies Is On Fire
Mar 11Intra-Cellular Therapies: Buoyant Caplyta Sales And Upcoming MDD Data Support Short-Term 'Buy'
Feb 11Intra-Cellular Therapies, Inc.'s (NASDAQ:ITCI) Price Is Out Of Tune With Revenues
Dec 24We're Interested To See How Intra-Cellular Therapies (NASDAQ:ITCI) Uses Its Cash Hoard To Grow
Nov 11Companies Like Intra-Cellular Therapies (NASDAQ:ITCI) Can Afford To Invest In Growth
Aug 07Here's Why We're Not At All Concerned With Intra-Cellular Therapies' (NASDAQ:ITCI) Cash Burn Situation
May 09After Leaping 31% Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Are Not Flying Under The Radar
Apr 17We're Not Very Worried About Intra-Cellular Therapies' (NASDAQ:ITCI) Cash Burn Rate
Jan 31Intra-Cellular Therapies (NASDAQ:ITCI) Is In A Good Position To Deliver On Growth Plans
Oct 25Intra-Cellular Therapies: What Lies Ahead
Sep 20Intra-Cellular cut to Neutral at Goldman on trends for antipsychotic drug
Aug 22Intra-Cellular Therapies GAAP EPS of -$0.92 misses by $0.15, revenue of $55.6M beats by $6.98M
Aug 09We're Hopeful That Intra-Cellular Therapies (NASDAQ:ITCI) Will Use Its Cash Wisely
Jul 09Intra-Cellular Therapies: A Dramatic Story
Jun 18Companies Like Intra-Cellular Therapies (NASDAQ:ITCI) Are In A Position To Invest In Growth
Apr 03Intra-Cellular: Not Participating In A Bear Market
Mar 31Intra-Cellular; Long-Term To Own With A Few FDA Approvals And Ability To Expand
Mar 08We're Not Very Worried About Intra-Cellular Therapies' (NASDAQ:ITCI) Cash Burn Rate
Dec 24Intra-Cellular's Second FDA Win Makes It A Great Long-Term Investment
Dec 21Intra-Cellular Therapies: A Leader In The Psychiatric Medicine Space
Nov 08We're Hopeful That Intra-Cellular Therapies (NASDAQ:ITCI) Will Use Its Cash Wisely
Aug 06Shareholder Returns
| ITCI | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -0.2% | 1.8% | 2.3% |
| 1Y | 5.4% | 16.0% | 26.8% |
Return vs Industry: ITCI underperformed the US Pharmaceuticals industry which returned 13.6% over the past year.
Return vs Market: ITCI underperformed the US Market which returned 27.2% over the past year.
Price Volatility
| ITCI volatility | |
|---|---|
| ITCI Average Weekly Movement | 8.3% |
| Pharmaceuticals Industry Average Movement | 10.3% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: ITCI has not had significant price volatility in the past 3 months.
Volatility Over Time: ITCI's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 610 | Sharon Mates | www.intracellulartherapies.com |
Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications.
Intra-Cellular Therapies, Inc. Fundamentals Summary
| ITCI fundamental statistics | |
|---|---|
| Market cap | US$6.94b |
| Earnings (TTM) | -US$110.87m |
| Revenue (TTM) | US$513.93m |
13.7x
P/S Ratio-63.6x
P/E RatioIs ITCI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ITCI income statement (TTM) | |
|---|---|
| Revenue | US$513.93m |
| Cost of Revenue | US$221.85m |
| Gross Profit | US$292.09m |
| Other Expenses | US$402.95m |
| Earnings | -US$110.87m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.05 |
| Gross Margin | 56.83% |
| Net Profit Margin | -21.57% |
| Debt/Equity Ratio | 0% |
How did ITCI perform over the long term?
See historical performance and comparison